Sage soars on postpartum depression dataSage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on Share XSage soars on postpartum depression datahttps://pharmaphorum.com/news/sage-soars-on-postpartum-depression-data/
FDA panel backs Sage’s novel antidepressant but turns down Alkermes’Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote Share XFDA panel backs Sage’s novel antidepressant but turns down Alkermes’https://pharmaphorum.com/news/fda-panel-backs-sages-novel-antidepressant-but-turns-down-alkermes/
